Injectable NADH Recalled for Sterility Concerns at Manufacturing Facility
Pharmacy Innovations is recalling NADH 10MG/ML injectable vials distributed nationwide due to lack of assurance of sterility. FDA inspection revealed insanitary conditions at the facility.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a Class II FDA recall of an injectable product where sterility assurance has been compromised due to identified insanitary manufacturing conditions. No illnesses or injuries have been reported, but injectable products with potential sterility failures represent a risk-of-harm situation that warrants a High severity rating.
Plain-English summary
Pharmacy Innovations is recalling NADH 10MG/ML (10ML VIAL) INJECTABLE, Rx Only, due to a lack of assurance of sterility. During an FDA inspection of the manufacturing facility located at 2936 W 17th St., Erie, PA, insanitary conditions were identified that could compromise product sterility.
The affected product was distributed nationwide. The recall applies to all units with code t20221108@46.
This is a serious concern because injectable products require strict sterility standards to prevent infection and other complications. Healthcare providers and patients who have received this product should contact their healthcare provider if they have any concerns.
The recalled product
- Product
- NADH 10MG/ML (10ML VIAL) INJECTABLE, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.
- Manufacturer
- Pharmacy Innovations
- Category
- Drug — Injectable
- Hazard
- sterility-failure
- contamination-risk
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- t20221108@46
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27